Feasibility Pilot Trial for the Trajectories of Recovery after Intravenous Propofol versus Inhaled Volatile Anesthesia (THRIVE) Pragmatic Randomized Clinical Trial
Authors' conclusion
It was feasible to enroll sufficient patients, adhere strongly to the randomized treatment allocation, and obtain adequate outcomes data at these two pilot sites for the THRIVE trial.
Study context
- Population
- Adults undergoing elective noncardiac surgery requiring GA at two US academic institutions
- Participants
- 300 adults · 2 sites
- Comparison
- TIVA with propofol vs inhaled volatile anaesthesia
- Total intravenousn = 149
- Inhaledn = 151reference
- Primary endpoint
- Feasibility: percentages of consent, intervention adherence and data completion vs predefined thresholds (10%, 80%, 90%)
Methodological detailsfeasibility pilot, multicentre, Surveys on POD 0, 1, 2, 7, 30 and 90, Enrolled September 2022 through March 2023
- Feasibility pilot
- Multicentre
- Surveys on POD 0, 1, 2, 7, 30 and 90
- Enrolled September 2022 through March 2023
Primary result
As reported in the abstract
Feasibility
| Group | Value | Adherence |
|---|---|---|
| Total intravenous | 95% (95% CI 92–99%) | 142 of 149 |
| Inhaled | 99% (95% CI 98–100%) | 150 of 151 |
Value
Total intravenous95% (95% CI 92–99%)
Inhaled99% (95% CI 98–100%)
Adherence
Total intravenous142 of 149
Inhaled150 of 151
- Consented of patients approached: 351 of 663
- 53%; 95% CI, 49 to 57%
- Complete data, QoR-15: 279 of 299
- 93%; 95% CI, 91 to 96%
- Complete data, modified Brice: 299 of 299
- 100% complete 95% CI, 100 to 100%
Original publication
Feasibility Pilot Trial for the Trajectories of Recovery after Intravenous Propofol versus Inhaled Volatile Anesthesia (THRIVE) Pragmatic Randomized Clinical Trial. Anesthesiology. Published 8 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →